Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX 3 CL1/CX 3 CR1 Pathway in Experimental Mouse Models of Systemic Sclerosis

To assess the preclinical efficacy and mechanism of action of an anti-CX CL1 monoclonal antibody (mAb) in systemic sclerosis (SSc). Cultured human dermal fibroblasts were used to evaluate the direct effect of anti-CX CL1 mAb on fibroblasts. In addition, bleomycin-induced and growth factor-induced mo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2019-11, Vol.71 (11), p.1923
Hauptverfasser: Luong, Vu H, Utsunomiya, Akira, Chino, Takenao, Doanh, Le H, Matsushita, Takashi, Obara, Takashi, Kuboi, Yoshikazu, Ishii, Naoto, Machinaga, Akihito, Ogasawara, Hideaki, Ikeda, Wataru, Kawano, Tetsu, Imai, Toshio, Oyama, Noritaka, Hasegawa, Minoru
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To assess the preclinical efficacy and mechanism of action of an anti-CX CL1 monoclonal antibody (mAb) in systemic sclerosis (SSc). Cultured human dermal fibroblasts were used to evaluate the direct effect of anti-CX CL1 mAb on fibroblasts. In addition, bleomycin-induced and growth factor-induced models of SSc were used to investigate the effect of anti-CX CL1 mAb on leukocyte infiltration, collagen deposition, and vascular damage in the skin. Anti-CX CL1 mAb treatment significantly inhibited Smad3 phosphorylation (P < 0.05) and expression of type I collagen and fibronectin 1 (P < 0.01) in dermal fibroblasts stimulated with transforming growth factor β1 (TGFβ1). In the bleomycin model, daily subcutaneous bleomycin injection increased serum CX CL1 levels (P < 0.05) and augmented lesional CX CL1 expression. Simultaneous administration of anti-CX CL1 mAb or CX CR1 deficiency significantly suppressed the dermal thickness, collagen content, and capillary loss caused by bleomycin (P < 0.05). Injection of bleomycin induced expression of pSmad3 and TGFβ1 in the skin, which was inhibited by anti-CX CL1 mAb. Further, the dermal infiltration of CX CR1+ cells, macrophages (inflammatory and alternatively activated [M2-like] subsets), and CD3+ cells significantly decreased following anti-CX CL1 mAb therapy (P < 0.05), as did the enhanced skin expression of fibrogenic molecules, such as thymic stromal lymphopoietin and secreted phosphoprotein 1 (P < 0.05). However, the treatment did not significantly reduce established skin fibrosis. In the second model, simultaneous anti-mCX CL1 mAb therapy significantly diminished the skin fibrosis induced by serial subcutaneous injection of TGFβ and connective tissue growth factor (P < 0.01). Anti-CX CL1 mAb therapy may be a novel approach for treating early skin fibrosis in inflammation-driven fibrotic skin disorders such as SSc.
ISSN:2326-5205
DOI:10.1002/art.41009